Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPPHIRE-I: Viekira Pak + Ribavirin in Treatment-Naïve Genotype 1 HCV
NCT01716585Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2012
- Primary completion
- Oct 2013
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial of paritaprevir, ombitasvir and dasabuvir in hepatitis C (HCV) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment. Started Nov 2012; status: completed.
02
Drugs
paritaprevirombitasvirdasabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01716585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01716585.